Skip to content

Author

M. Kamdar

We have 3 of 233 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

TP53-Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes by Treatment Modality: A Multicenter Cohort From 14 US Centers.

Advances in the treatment of large B-cell lymphoma (LBCL) have expanded therapeutic options beyond conventional chemoimmunotherapy to include cellular and targeted therapies. There is growing interest in identifying subsets of LBCL that may benefit from these novel approaches based on histopathologic and molecular feat...

C. Duarte, G. Bosma, Diana Abbott et al. · 0 citations
Review Open access Sep 2026

Sequencing CD19-targeted therapies in patients with relapsed/refractory large B-cell lymphoma: A narrative review.

The unmet needs in patients with high-risk disease and the challenges of sequencing these therapeutic strategies are discussed, while providing expert clinical practice recommendations to optimize patient outcomes are provided.

P. Caimi, Romano Danesi, G. Iacoboni et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.